Casdin Capital »

Bridgebio Oncology Therapeut shares owned by Casdin Capital

Quarter-by-quarter ownership of Bridgebio Oncology Therapeut shares owned by Casdin Capital from 13F filings

Historical chart of Casdin Capital investment in Bridgebio Oncology Therapeut

Tip: Access up to 7 years of quarterly data

All positions including Bridgebio Oncology Therapeut held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bridgebio Oncology Therapeut by Casdin Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $3.3M 282k 11.58

More positions owned by Casdin Capital

Genedx Holdings Corp Com Cl A (WGS)
Biolife Solutions Com New (BLFS)
Revolution Medicines (RVMD)
D Fluidigm Corp Del (LAB)
Avidity Biosciences Ord (RNA)
Relay Therapeutics (RLAY)
Illumina (ILMN)
Structure Therapeutics Sponsored Ads (GPCR)
Beam Therapeutics (BEAM)
Alnylam Pharmaceuticals (ALNY)
Tempus Ai Cl A (TEM)
Neurogene (NGNE)
Maze Therapeatics (MAZE)
Prime Medicine (PRME)
Silverback Therapeutics (SPRY)

View all positions for Casdin Capital

Top funds holding Bridgebio Oncology Therapeut

Cormorant Asset Management
Deerfield Management Company
Omega Fund Management
Wellington Management Company
Alphabet
EcoR1 Capital
Enavate Sciences GP
Citadel Advisors
BlackRock
Novo A/S
Paradigm Biocapital Advisors
Adage Capital Partners GP
Eventide Asset Management
Laurion Capital Management
Octagon Capital Advisors

View all funds holding Bridgebio Oncology Therapeut